Passage Bio to Present at Chardan’s 6th Annual Genetic Medicines Conference

Rhea-AI Summary

Passage Bio (NASDAQ: PASG) announced that CFO Simona King will present at the Chardan Genetic Medicines Conference from October 3-4, 2022, in New York City. The presentation will be a fireside chat on October 3 at 1:00 p.m. ET, and it will be accessible via live webcast on their Investors & Media page. Passage Bio focuses on developing therapies for central nervous system disorders and is advancing multiple clinical programs aimed at conditions like GM1 gangliosidosis and Krabbe disease. More details can be found on their official website.

PHILADELPHIA, Sept. 26, 2022 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system (CNS) disorders, today announced that Simona King, chief financial officer of Passage Bio, will present at the upcoming Chardan Genetic Medicines Conference being held from October 3-4, 2022 in New York City.

Format: Fireside Chat
Date: Monday, October 3^rd
Time: 1:00 p.m. ET
Location: New York, NY

A live webcast of these events will be available on the Investors & Media section of Passage Bio’s website at investors.passagebio.com. A replay of the presentation will be available for 30 days following the event.

About Passage Bio
Passage Bio (Nasdaq: PASG) is a clinical-stage genetic medicines company on a mission to provide life-transforming therapies for patients with CNS diseases with limited or no approved treatment options. Our portfolio spans pediatric and adult CNS indications, and we are currently advancing three clinical programs in GM1 gangliosidosis, Krabbe disease and frontotemporal dementia with several additional programs in preclinical development. Based in Philadelphia, PA, our company has established a strategic collaboration and licensing agreement with the renowned University of Pennsylvania’s Gene Therapy Program to conduct our discovery and IND-enabling preclinical work. Through this collaboration, we have enhanced access to a broad portfolio of gene therapy candidates and future gene therapy innovations that we then pair with our deep clinical, regulatory, manufacturing and commercial expertise to rapidly advance our robust pipeline of optimized gene therapies. As we work with speed and tenacity, we are always mindful of patients who may be able to benefit from our therapies. More information is available at www.passagebio.com.

For further information, please contact:

Passage Bio Investors:
Stuart Henderson
Passage Bio
267-866-0114
shenderson@passagebio.com

Passage Bio Media:
Mike Beyer
Sam Brown Inc. Healthcare Communications
312-961-2502
MikeBeyer@sambrown.com

FAQ

When is Passage Bio's presentation at the Chardan Genetic Medicines Conference?

Passage Bio's presentation will be on October 3, 2022, at 1:00 p.m. ET.

Who will present for Passage Bio at the conference?

Simona King, the chief financial officer of Passage Bio, will present at the conference.

Where can I watch the live webcast of Passage Bio's presentation?

The live webcast can be accessed on Passage Bio's Investors & Media section on their website.

What therapies is Passage Bio developing?

Passage Bio is developing therapies for CNS disorders, including GM1 gangliosidosis, Krabbe disease, and frontotemporal dementia.

What is the purpose of Passage Bio's participation in the Chardan Genetic Medicines Conference?

The conference provides an opportunity for Passage Bio to showcase its clinical programs and advancements in genetic medicine.